12,523 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Two Sigma Investments LP

Two Sigma Investments LP purchased a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,523 shares of the company's stock, valued at approximately $781,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Braidwell LP purchased a new stake in TransMedics Group during the 4th quarter valued at $57,493,000. Norges Bank bought a new position in shares of TransMedics Group during the 4th quarter valued at $22,861,000. Dimensional Fund Advisors LP lifted its holdings in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after buying an additional 253,624 shares during the period. Emerald Advisers LLC lifted its holdings in shares of TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after buying an additional 220,804 shares during the period. Finally, FIL Ltd lifted its holdings in shares of TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after buying an additional 218,961 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

TMDX has been the topic of a number of recent research reports. Oppenheimer raised their target price on TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 target price (up from $125.00) on shares of TransMedics Group in a report on Wednesday. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 3rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.11.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now directly owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Weill sold 732 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the sale, the director now directly owns 12,134 shares of the company's stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,732 shares of company stock worth $1,416,710 in the last ninety days. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $139.05 on Friday. The stock has a market capitalization of $4.70 billion, a PE ratio of 147.93 and a beta of 2.10. The firm has a 50 day moving average of $101.54 and a two-hundred day moving average of $80.28. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. During the same period in the previous year, the company earned $0.35 EPS. The company's revenue for the quarter was up 48.2% on a year-over-year basis. On average, research analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.